Globus Medical, Inc. logo

Globus Medical, Inc.

GMED

NYSEHealthcareMedical - Devices

Previous close

$86.91

+$1.24 · +1.45%

Aug 21, 4:00 PM ET

GMED company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

86

Deep Value

Momentum

37

Weakening

Sentiment

79

Bullish

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Keith W. Pfeil
Listed since
Aug 3, 2012
Employees
6,000

Market position

Day range

Current $86.91

52-week range

Current $86.91

Open
$85.64
Previous close
$85.67
Volume
651.82K
0.39× average
Average volume
1.67M
Average daily volume
Market cap
11.72B USD
Beta
0.95
Market reference 1
50-day average
$80.6208
+7.80% above average
200-day average
$85.7055
+1.41% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
21.89×
P/B (TTM)
2.47×
P/S (TTM)
3.73×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
68.55%
Operating margin
20.75%
Net margin
17.03%

Financial health

Debt / equity
0.02×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends82%54%25%-3%Gross margin, FY2021: 75.03%Gross margin, FY2022: 74.22%Gross margin, FY2023: 65.05%Gross margin, FY2024: 58.90%Gross margin, FY2025: 67.41%Operating margin, FY2021: 17.95%Operating margin, FY2022: 22.29%Operating margin, FY2023: 8.49%Operating margin, FY2024: 6.59%Operating margin, FY2025: 16.33%Net margin, FY2021: 15.57%Net margin, FY2022: 18.59%Net margin, FY2023: 7.83%Net margin, FY2024: 4.09%Net margin, FY2025: 18.30%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 75.03%. Gross margin FY2022 74.22%. Gross margin FY2023 65.05%. Gross margin FY2024 58.90%. Gross margin FY2025 67.41%. Operating margin FY2021 17.95%. Operating margin FY2022 22.29%. Operating margin FY2023 8.49%. Operating margin FY2024 6.59%. Operating margin FY2025 16.33%. Net margin FY2021 15.57%. Net margin FY2022 18.59%. Net margin FY2023 7.83%. Net margin FY2024 4.09%. Net margin FY2025 18.30%.

Income trends

Revenue

2.94B USD+16.65%

Operating income

479.8M USD+189.05%

Net income

537.9M USD+422.31%
Income trends across reported periods3.22B USD2.09B USD953.76M USD−180.61M USDRevenue, FY2021: 958.1M USDRevenue, FY2022: 1.02B USDRevenue, FY2023: 1.57B USDRevenue, FY2024: 2.52B USDRevenue, FY2025: 2.94B USDOperating income, FY2021: 171.95M USDOperating income, FY2022: 227.95M USDOperating income, FY2023: 133.14M USDOperating income, FY2024: 165.99M USDOperating income, FY2025: 479.8M USDNet income, FY2021: 149.19M USDNet income, FY2022: 190.17M USDNet income, FY2023: 122.87M USDNet income, FY2024: 102.98M USDNet income, FY2025: 537.9M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 958.1M USD. Revenue FY2022 1.02B USD. Revenue FY2023 1.57B USD. Revenue FY2024 2.52B USD. Revenue FY2025 2.94B USD. Operating income FY2021 171.95M USD. Operating income FY2022 227.95M USD. Operating income FY2023 133.14M USD. Operating income FY2024 165.99M USD. Operating income FY2025 479.8M USD. Net income FY2021 149.19M USD. Net income FY2022 190.17M USD. Net income FY2023 122.87M USD. Net income FY2024 102.98M USD. Net income FY2025 537.9M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.94B USD2.52B USD1.57B USD1.02B USD958.1M USD
Cost of goods sold957.8M USD1.04B USD548.17M USD263.73M USD239.22M USD
Gross profit1.98B USD1.48B USD1.02B USD759.12M USD718.88M USD
Research and development185M USD163.75M USD124.01M USD73.02M USD97.35M USD
Selling, general, and administrative1.32B USD981.05M USD643.41M USD432.12M USD408.15M USD
Operating expenses1.5B USD1.32B USD887.16M USD531.17M USD546.93M USD
Interest income7.14M USD20.13M USD14.23M USD9.3M USD
Interest expense4.19M USD
Depreciation and amortization120M USD254.02M USD144.73M USD68.25M USD69.87M USD
Operating income479.8M USD165.99M USD133.14M USD227.95M USD171.95M USD
Net income537.9M USD102.98M USD122.87M USD190.17M USD149.19M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$98.88

13.77% upside
Past 12 months12-month forecastHigh $117Average $98.88Low $80.00

Rating distribution

36 ratings
Strong buy00%
Buy2672%
Hold925%
Sell13%
Strong sell00%

GMED news

GMED peers

ETFs holding GMED

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research GMED

research.disclaimer